Monopar to Present at the Jefferies Radiopharma Innovation Summit

WILMETTE, Ill., March 28, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler Robinson, MD, Monopar’s Chief Executive Officer, will present at the Jefferies Radiopharma Innovation Summit next week.

Presentation Details:

Date: April 3, 2023Time: 1:00 – 1:30 pm Location: Jefferies Conference Center, NYC, New York

About Monopar Therapeutics Inc.

Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of camsirubicin (Phase 1b) for the treatment of advanced soft tissue sarcoma; a late-stage preclinical antibody, MNPR-101, for radiopharmaceutical use in advanced cancers; and an early-stage camsirubicin analog, MNPR-202, for various cancers. For more information, visit: www.monopartx.com.

CONTACT:

Monopar Therapeutics Inc. Investor RelationsKim R. TsuchimotoChief Financial Officer[email protected]

Follow Monopar on social media for updates:  Twitter: @MonoparTx  LinkedIn: Monopar Therapeutics

Source: Monopar Therapeutics Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Solerus Announces Plans for New Growth Fund for High-Net-Worth Investors
• Tax Lien Wealth Builders Named No. 3212 on the 2026 Inc. 5000 List
• Zum Expands to New York, Marking 19th State Nationwide